Publication | Closed Access

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

VaccinationVaccine TargetMalariaImmunologyParasite GenomicsDouble-blind SafetyWestern KenyaMedicineVaccine ResearchPhase 1Parasitology